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The aetiopathogenesis of cardiovascular diseases (CVD) is multifactorial.  Adverse blood 
pressure (BP) is a major independent risk factor for epidemic CVD affecting about 40% of the 
adult population worldwide and resulting in significant morbidity and mortality.  Metabolic 
phenotyping of biological fluids has proven its application in characterising low molecule 
weight metabolites providing novel insights into gene-environmental-gut microbiome 
interaction in relations to a disease state.  In this review, we synthesise key results from the 
International Study of Macro/Micronutrients and Blood Pressure (INTERMAP) Study, a cross-
sectional epidemiological study of 4,680 men and women aged 40-59 years from Japan, the 
WĞŽƉůĞ ?Ɛ ZĞƉƵďůŝĐŽĨŚŝŶĂ ? the United Kingdom, and the United States.  We describe the 
advancements we have made on: 1) analytical techniques for high throughput metabolic 
phenotyping; 2) statistical analyses for biomarker identification; 3) discovery of unique food-
specific biomarkers; and 4) application of metabolome-wide association (MWA) studies to 
gain a better understanding into the molecular mechanisms of cross cultural and regional BP 





Adverse blood pressure (BP) (prehypertension and hypertension) is a major 
independent risk factor for epidemic cardiovascular diseases (CVD), affecting about 40% of 
the adult population worldwide.1-4  Its causation is multifactorial encompassing both 
environmental -- diet, other aspects of lifestyle -- and genetic factors.  Public health policies 
aiming to improve the prevention of high BP and/or maintain optimal BP level typically involve 
efforts to tackle known modifiable risk factors such as reduction of high salt intake, 
moderation of alcohol intake, maintenance of normal weight and increased physical activity.  
While large-scale genome-wide association studies (GWAS) have identified common variants, 
novel loci and pathways associated with BP,5-9 the genetic contribution to BP variation in the 
population is modest.5, 7, 8  Despite the effectiveness of non-pharmacological approaches to 
BP control, many people with high BP are reliant on antihypertensive drugs or BP remains 
untreated or poorly controlled.10, 11 
The INTERnational study of MAcro/micronutrients and blood Pressure (INTERMAP) is 
a cross-sectional epidemiological study of 4,680 men and women aged 40-59 years from 
Japan, the People's Republic of China, the United Kingdom, and the United States 
(www.clinicaltrials.gov NCT00005271).12  The main aim of the INTERMAP Study is to 
investigate the aetiology of adverse BP with emphasis on studying diet-BP associations (Figure 
1).12, 13  Participants were selected randomly from population lists, stratified by age/sex.  Each 
participant attended four visits, visits 1 and 2 on consecutive days, visits 3 and 4 on 
consecutive days on average 3 weeks later.  At each of the four visits, BP was measured twice 
with a random zero sphygmomanometer and dietary data were collected by a trained 
certified interviewer with use of the in-depth multi-pass 24-h recall method.14  Height and 
weight were measured twice on the first and third visits. On the first visit, questionnaire data 
were obtained on demographic, medical history, medication intake, and other possible 
confounders.  Each participant provided two 24-h urine collections, start and end timed at 
the research centre.  The two timed 24-hour urine collections per person on each of the 4,680 
INTERMAP participants are a pivotal feature of study design that enabled the introduction of 
metabolome-wide association (MWA) study (see later section).  The study received 




In the past decade, the INTERMAP Study, has added new knowledge to the limited 
data previously available on the effects of nutritional factors on BP.15  These advances include 
the inverse relationship between BP and intakes of vegetable protein,16 glutamic acid,17 total 
and insoluble fibre,18 raw and cooked vegetables,19 total polyunsaturated fatty acids (PFA) 
and linoleic acid,20 oleic acid from vegetable sources,21 total omega-3 fatty acids and linolenic 
acid,22 phosphorus (P), calcium (Ca) and magnesium (Mg),23 non-heme iron (Fe) and total Fe,24 
and starch25; and the direct associations of sugars (fructose, glucose and sucrose),26 
cholesterol,27 glycine and alanine,28 raw fruits,29 and oleic acid from animal sources.21  The 
INTERMAP Study showed that diet-induced metabolic acidosis was positively associated with 
BP (not significant after controlling for body mass index, BMI);30 whereas a cohort of over 
61,000 persons reported a positive association of metabolic acid load (such as serum 
bicarbonate, urine acidity) and cardiovascular mortality.31  While the INTERMAP Study 
reported a small non-significant inverse relationship between urinary Mg and BP32;  the World 
Health Organization-coordinated Cardiovascular Diseases and Alimentary Comparison 
(CARDIAC) Study showed urinary Mg to creatinine ratio was inversely associated with CVD 
risk factors such as BMI and BP.33  Although important advances have been made by the 
INTERMAP Study in improving understanding of the aetiology of high BP, together with other 
research into the physiology of BP regulation such as the control of kidney fluid and salt 
balance via the renin-angiotensin-aldosterone system,34-36 sympathetic nervous system 
activity,37, 38 and the role of structure and function of blood vessels,39 gaps still remain in our 
knowledge of the causes and mechanisms of adverse BP levels.  New approaches are needed 
to enhance understanding of the multifactorial aetiopathogenesis of BP. 
High resolution proton nuclear magnetic resonance (NMR) spectroscopy have been 
successfully applied for the investigation of drug metabolism and toxicology as well as disease 
development within a biological system, using biological fluids such as urine, plasma/serum 
as well as bile, cerebrospinal fluids and dialysates.40, 41  Recent studies have shown the 
importance of the gut-microbiome in the aetiology of a number of chronic diseases such as 
atherosclerosis, diabetes and the metabolic syndrome, obesity as well as raised BP.42-47 
Metabolic phenotyping of biological fluids using spectroscopic methods enables the 
investigation of gene-environmental-gut microbiome interactions on disease risk and is 
therefore an attractive approach for gaining new insights into BP mechanisms and its 
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associated pathways.45, 48-50  The INTERMAP Study has capitalised on the evolving 
technologies in metabolic phenotyping to enhance its rich nutrient and anthropometric data 
by incorporating this top down system approach to investigate the association of BP and 
urinary markers that are linked to environmental exposures including diets and 
xenometabolomes.48-52  This review demonstrates the key progress made by the INTERMAP 
Study and the introduction of the metabolome-wide association (MWA) study on diet and 
BP.13  However, readers may wish to refer to other recent reviews on the principles of 
metabolic phenotyping.53-55  
Analytical method development 
Metabolic phenotyping involves the application of high-throughput advanced 
spectroscopic methods, such as proton nuclear magnetic resonance (1H NMR) spectroscopy 
and mass spectroscopy (MS), to biological samples. In INTERMAP comprehensive metabolic 
phenotyping by 1H NMR spectroscopy of the two 24-h urine samples from each participant 
(N=4,630) has been performed.13  The repeatability, accuracy and stability of the 1H NMR 
spectral profiles were evaluated and overall analytical reproducibility of the 1H NMR was 
found to be >98%.56  In INTERMAP, boric acid (borate, a preservative known to bind covalently 
to vicinal diols and some amino acids) was added to the urine collection jars in the field to 
prevent bacterial overgrowth.  The effect of the boric acid on the 1H NMR urinary spectra was 
also assessed.37, 38  It was shown that the overall changes in the urinary 1H NMR spectral 
profile caused by borate addition were negligible compared with the physiological and 
metabolic differences between individuals.57  These studies have led to recommendations for 
improved sample preparation and handling of urine samples, as well as processing methods 
for large-scale epidemiologic research.58 
In addition to metabolic phenotyping via 1H NMR spectroscopy, we obtained extensive 
data on 20 urinary amino acids using conventional cation-exchange chromatography followed 
by post-column derivatisation (Biochrom 20 and Biochrom 30).  These data provide a unique 
population based dataset on urinary amino acid excretion levels in different populations. We 
then applied gas chromatography mass spectrometry (GC ?MS) and liquid chromatography ?
tandem mass spectrometry (LC ?MS/MS) for high throughput urinary amino acid analysis and 
compared their sample preparation, run-time, number of analytes amenable to 
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quantification, cost, limit of quantification (LOQ), reproducibility and validity with 
conventional amino acid analysis.59  The amount of urine needed for GS-MS and LC-MS/MS 
were 40-50 µL, much less than the 200 µL required for the amino acid analyser.  Moreover, 
the run-time for the amino acid analyser was approximately 5 to 6 times longer than that of 
GC-MS and LC-MS/MS.  The Pearson correlation coefficients of amino acids measured by GC-
MS and the amino acid analyser ranged from 0.80 (tryptophan) to 0.98 (glycine); correlation 
coefficients comparing LC-MS/MS with the amino acids analyser ranged from 0.56 (arginine) 
to 0.95 (lysine).  Our findings showed that GC ?MS offered higher reproducibility and 
completely automated sample pre-treatment compared with LC ?MS/MS and conventional 
amino acid analysis, which on the other hand covered more amino acids and related amines. 
 We also applied ultra performance liquid chromatography triple quadruple tandem 
mass spectrometry (UPLC-TQ-MS/MS) for simultaneous detection (both positive and negative 
electrospray ionization modes) and quantification of three gut microbial co-metabolites, 
phenylacetylglutamine (PAG), 4-cresyl sulphate and hippurate in the urinary specimens from 
2,000 INTERMAP US participants.60  This targeted high-throughput UPLC-TQ-MS/MS method 
was developed specifically to measure these gut microbial co-metabolites, which may be 
implicated in obesity61 and other chronic diseases such as cardiovascular and kidney 
disease.62, 63  Following the US Food and Drug Administration (FDA) guidelines, the imprecision 
(CV: coefficient of variation) and inaccuracy (recovery) of the method were assessed using 
replicates of quality control (QC) urine samples at different concentration levels.  The CV and 
recovery were found to be within acceptable limits of FDA guidelines.  The study 
demonstrated the applicability of metabolic phenotyping by UPLC-TQ-MS/MS in a large scale 
epidemiological study. 
Statistical method development 
Metabolomic data pose special challenges to statistical analysis, including high 
dimensionality, strong co-linearity, non-linear and highly complex spectral profiles, and 
presence of structured and unstructured noise (due to within- and between-individual 
variability).64-68  Spectroscopic data are first pre-processed, including spectral alignment and 
normalisation of the full-resolution spectral data.  Multiple statistical strategies are then 
applied, including use of both unsupervised and supervised multivariate data analysis 
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techniques to extract information from the data.69  Principal component analysis (PCA) is 
routinely used to identify main sources of variation in the data, and detect outlying values 
with the goal of providing the most compact representation of the data.64, 67-69  Hierarchical 
cluster analysis (HCA) is another method widely used in exploratory data analysis to provide 
an overview of the data by grouping phenotypes according to their similarity, without 
assuming any prior knowledge of the data.64, 68, 69  Other techniques include partial least 
squares (PLS), orthogonal partial least squares (O-PLS), and orthogonal partial least squares 
discriminant analysis (OPLS-DA) 70-72 aiming to extract discriminatory metabolic signals  from 
the datasets are often applied after the initial exploratory analysis; whilst statistical 
spectroscopy methods, accommodating complex spectral data structure and correlations, 
such as statistical total correlation spectroscopy (STOCSY), 73, 74 iterative-STOCSY (I-STOCSY),75 
cluster analysis statistical spectroscopy (CLASSY),76 and subset optimization by reference 
matching (STORM),77 are used to aid the biomarker identification process.  Statistical 
Heteroscpectroscopy (SHY) is a statistical strategy for the analysis of multiple spectroscopic 
datasets e.g. 1H NMR and UPLC-MS on the same samples.  This method has enable the 
characterisation of drug metabolites (xenometabolome) in epidemiology study.78  Other 
recent statistical spectroscopic methods include statistical homogeneous cluster 
spectroscopy (SHOCSY)79 and automatic spectroscopic data categorisation by clustering 
analysis (ASCLAN).80  These methods aim to remove the influence of irrelevant interferences 
within the dataset to enhance the biomarkers selection process,79 and to reliably differentiate 
potential discriminatory markers from non-discriminatory markers in a biological dataset,80  
respectively.  Figure 2 shows the steps of statistical analysis of INTERMAP NMR metabolic 
phenotyping data.13, 81, 82 
In MWA studies, hundreds to thousands of biomarkers are assayed leading to data 
that are highly multivariate and co-linear.  In order to detect statistically significant 
relationships between molecular variables and phenotype, we defined the metabolome-wide 
significance level (MWSL), a threshold required to control the family wise error rate (FWER) 
through a permutation approach.83  Using the spectra of the INTERMAP Chinese participants 
(N=836) as the reference population, we investigated the influence of spectral resolution and 
the number of variables in the NMR spectra, and examined population heterogeneity by 
repeating the analysis in the INTERMAP US population samples (N=2,164).  Results showed 
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that MWSL of 2 × 10-5 and 4 × 10-6 for a FWER of 0.05 and 0.01 could be used as a benchmark 
for NMR based MWA studies of human urine. For the subsequent INTERMAP MWA studies, 
MWSL of 4.0x10-6 is used to identify significant metabolic features, as a conservative estimate 
taking account of the high degree of co-linearity in urinary NMR spectral data.81, 82 A similar 
approach may be used for MS based MWA studies. 
Novel biomarker discovery 
Identification of unknown discriminatory metabolite is a key bottleneck in MWA 
study since the human metabolomes is still largely unknown.  Elucidating the chemical 
structure of unknown metabolite is often labour-intensive and requires multiple analyses 
using a series of analytical experiment.  Within the INTERMAP, we have been successful in 
identification of a number of metabolites including metabolites derived from dietary and 
drug intake.84-87   
Ethyl glucoside 
The INTERMAP MWA study has discovered novel metabolite related to the intake of 
alcohol amongst the Chinese and Japanese population samples.  From the 1H NMR urinary 
spectra, a doubleƚĂƚɷ ? ? ? ?ĐŽƌƌĞƐƉŽŶĚŝŶŐƚŽĞƚŚǇůŐůƵĐŽƐŝĚĞǁĂƐŽďƐĞƌǀ ĚĂŶĚŝƚǁĂƐĚĞƌŝǀĞĚ
following the ingestion of rice wine and sake.84  This doublet was not observed amongst the 
western population samples in the INTERMAP Study.   
Proline betaine  
We used metabolic phenotyping by 1H NMR spectroscopy to detect an increased 
excretion of proline betaine, tartaric acid and hippurate after fruit consumption compared 
with baseline diet in a dietary intervention study.85  We then measured concentrations of 
proline betaine in selected fruit and commercially available fruit juices by 1H NMR 
spectroscopy optimized for quantification of this compound.  All citrus fruit tested contained 
proline betaine; concentrations varied from 75 mg/L in orange squash to 1,316 mg/L in orange 
juice from concentrate.  After consumption of 250 ml orange juice we found a singlet peak at 
ɷ ? ? ? ? ? ƌĞƉƌĞƐĞŶƚŝŶŐ ƚŚĞ ,3 moiety of proline betaine.  Most proline betaine excretion 
occurred in the first 14 hours after consumption, peaked at the 2-hr post-intervention urine 
collection and declined to almost baseline level after 24 hours. 
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The 24-h dietary recalls of INTERMAP UK participants were then assessed to validate 
the use of proline betaine excretion as a biomarker of citrus fruit consumption and as a 
surrogate marker of healthier eating patterns.85  Proline betaine excretion differed 
significantly between individuals with no recorded citrus consumption in their 24-h dietary 
recall data and individuals with recorded citrus consumption (P<0.0001).  Those who reported 
citrus consumption and had higher levels of proline betaine excretion also showed a healthier 
nutrient profile with higher intake of vegetable protein, and lower intakes of total fat, trans 
fatty acids, cholesterol and animal protein, lower urinary sodium-potassium (Na/K) ratio, 
lower body mass index (BMI) and lower systolic BP compared with non-citrus consumers.  
These findings provide proof that metabolic phenotyping can discover novel dietary 
biomarkers that can be used to validate dietary assessment in large-scale epidemiologic data. 
Acetaminophen and ibuprofen 
Although the metabolism of commonly used analgesics such as acetaminophen and 
ibuprofen has been widely described40, 41, 88, 89, within the INTERMAP Study, we showed that 
we could detect urinary metabolite signatures related to commonly used analgesics such as 
acetaminophen and ibuprofen,86  enabling the use of metabolic signatures to verify the self-
reported data.87 We applied PCA on 1H NMR spectra of US participants and identified 413 
urine samples containing acetaminophen and its metabolites (acetaminophen users) and 
then applied OPLS-DA analysis on a subset of 70 urine samples from acetaminophen users 
and 70 urine samples from acetaminophen non-users.86  The OPLS-DA loading coefficient plot 
showed that differentiation between acetaminophen users vs. non-users primarily resulted 
from the presence of acetaminophen and its metabolites acetaminophen glucuronide, 
acetaminophen sulfate, and the acetylcysteine conjugate of acetaminophen.  Similarly, a PCA 
model was constructed to identify urine samples of ibuprofen users, and OPLS-DA was 
performed on a subset of urine samples.  The OPLS-DA loading coefficient plot showed that 
participants who had ingested ibuprofen were differentiated from non-users by the presence 
of 2-hydroxy, carboxy, and glucuronide conjugates of ibuprofen in the urinary NMR spectra.   
We then used these metabolic signatures to verify self-reported analgesic use of 
INTERMAP particpants.87 Urinary spectra of UK (Belfast, N=216) and US (Chicago, N=280) 
participants were inspected for the presence or absence of metabolites in spectral regions 
containing acetaminophen and ibuprofen.87  These spectra were used to construct prediction 
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models (sensitivity > 98%) based on self-reported analgesic use; overall rates of concordance 
between questionnaire data and urinary spectra were high for both populations: 83.8% (95% 
confidence interval, CI: 78.9, 88.7) in Belfast and 81.1% (95% CI: 76.5, 85.7) in Chicago.  Overall 
rates of under-detection of acetaminophen and ibuprofen were low (about 1%) and were 
comparable for both Belfast and Chicago.  We then applied these prediction models to 9,260 
urine spectra to evaluate reported analgesic use from self-reported questionnaire.  High-level 
concordance was observed between self-reported analgesic use and 1H NMR-detected 
urinary acetaminophen and/or ibuprofen metabolites for all Western population samples, an 
overall concordance of 70.5% (95% CI: 68.7, 72.2).  Our findings demonstrated the efficacy of 
an objective 1H NMR-based method for validation of self-reported data on analgesic use, 
detecting an underreporting rate of approximately 15% in the INTERMAP Study.  This MWA 
approach has demonstrated the potential of metabolic phenotyping in reducing recall bias 
and other biases in epidemiologic studies for a range of substances, including 
pharmaceuticals, dietary supplements, and foods. 
INTERMAP Metabolome-Wide Association Study 
INTERMAP is the first large-scale human population MWA study on diet and BP, using 
an exploratory analytical approach to investigate metabolic phenotype variation across and 
within 17 population samples in East (China and Japan) and West (UK and US) based on 1H 
NMR spectroscopy.13  Using a hierarchical clustering algorithm, we investigated 
similarity/dissimilarity between populations based on their urinary profiles. East Asian and 
Western populations had well-differentiated metabolic phenotypes (Figure 3). Among the 
East Asian samples, Japan was differentiated from China, and within China, North China was 
differentiated from South despite similar genetic background.  Using O-PLS-DA70, 73 we 
reported significant differences of metabolic profiles among these populations; 
discriminatory metabolites included gut microbial-host co-metabolites (hippurate, PAG and 
methylamines), amino acids (alanine, lysine, taurine), dietary related metabolites (e.g., ethyl 
glucoside, trimethylamine-N-oxide), compounds related to energy metabolism 
(acetylcarnitine), and tricarboxylic acid cycle intermediates (succinate and citrate).  Four 
discriminatory metabolites reflecting diet and gut microbial activities, alanine, formate, 
hippurate and N-methylnicotinate (NMNA), were then quantified from the 1H NMR urinary 
spectral profiles.  We found that alanine was highly correlated with 2-oxoglutarate (metabolic 
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linkage via glutamate-pyruvate transaminase activity) and with formate (pyruvate/Co-A 
metabolism), and hippurate was highly correlated with NMNA (renal transporter/secretion 
mechanisms).  In multiple linear regression models, both formate and hippurate were 
inversely associated with systolic and diastolic BP, and alanine was positively associated with 
BP. 
More detailed analysis was later performed on the Chinese population samples.81  We 
found that urinary metabolites significantly different between northern and southern 
Chinese, reflecting the variations in dietary pattern as well as CVD risk between these two 
populations;  higher in northern than southern Chinese populations included dimethylglycine, 
alanine, lactate, branched-chain amino acids (isoleucine, leucine, valine), N-acetyls of 
glycoprotein fragments (including uromodulin), N-acetyl neuraminic acid, 
pentanoic/heptanoic acid, and methylguanidine; metabolites significantly higher in the south 
included gut microbial-host co-metabolites (hippurate, 4-cresyl sulfate, PAG, 2-
hydroxyisobutyrate), succinate, creatine, scyllo-inositol, proline betaine, and trans-aconitate.  
Compared to the south, northern Chinese had higher BMI, less favourable diet including lower 
Ca, Mg and P intakes, higher 24-h urinary Na excretion, higher urinary Na/K ratio excretion, 
and higher BP (Table 1).90  The significant north-south differences in BP, BMI and diet90-92 are 
reflected in geographic variations in both CVD incidence and mortality rates, with higher rates 
in the north than the south.93-95  The INTERMAP MWA study indicates the likely importance 
of environmental influences (e.g., diet), endogenous metabolism, and mammalian-gut 
microbial co-metabolism, in helping to explain north-south China differences in CVD risk.  
The INTERMAP Study confirmed that African Americans (AA) had higher systolic and 
diastolic BP compared to non-Hispanic white Americans (NHWA)82 and this BP difference, in 
part, was due to less favourable multiple nutrient intake by AA, with lower intakes of fruits, 
vegetables, and dairy products, and lower intakes of vegetable protein, starch, fibre, K, Ca, 
Mg, P compared with that of whites. In addition, there was greater obesity prevalence among 
black compared with white women. 82 96 1H NMR spectra of the INTERMAP US participants 
showed that urinary metabolites significantly higher in AA than in NHWA included creatinine, 
3-hydroxyisovalerate, N-acetyls of glycoprotein fragments, dimethylglycine, lysine, N-acetyl 
neuraminic acid, leucine, dimethylamine, taurine, and 2-hydroxy-isobutyrate; metabolites 
significantly higher in NHWA included trimethylamine, NMNA, hippurate, and succinate 
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(Figure 4).82  The mean values of urinary hippurate (2.9 mmol/24-h for AA men, vs. 4.1 
mmol/24-h for NHWA men, P<5x10-9) and NMNA (0.24 mmol/24-h for AA men, vs. 0.42 
mmol/24-h for NHWA men, P<3x10-10) were significantly lower in AA compared to NHWA. 
Multiple linear regression was used to examine these AA-NHWA differences in dietary and 
urinary metabolites in relation to BP; multiple foods, nutrients and metabolites accounted for 
part of the higher BP among AA.  
Summary 
Over recent years, major advances have been made in the metabolic phenotyping of 
epidemiological samples. The advancement in the analytical techniques and the development 
of new statistical data analysis tools have enabled the identification of novel metabolic 
phenotypes associated with diet (including Na intake), xenobiotics and BP.  The findings of 
the INTERMAP MWA study may provide insights into molecular pathways underlying complex 
biological processes such as adverse BP levels.  We envisage that future studies will include 
the generation of testable hypotheses based on the findings from the INTERMAP MWA study.  
Moreover, the increasing number of population based cohort studies, which also apply MWA 
approach, will undoubtedly contribute to our understanding on the key mechanism that are 
associated with CVD.  As noted above, metabolomic data with hundreds to thousands of 
biomarkers being assayed, are highly multivariate, co-linear and noisy, with potential for false 
positive findings; it is also always a possibility but unlikely that phenotypes are specific to 
INTERMAP Study populations and not generalizable; replication studies are needed. 
Nonetheless, it is reasonable to state at this juncture that INTERMAP findings to date have 
demonstrated significant independent relationships of several nutrients/foods/eating 
patterns/metabolites to BP, thereby moving the field forward in exciting and unprecedented 
ways. 
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Figure Legend  
Figure 1  INTERMAP metabolome-wide association (MWA) studies.12, 13 
Figure 2  Steps involved in the statistical analysis of INTERMAP NMR metabolic 
phenotyping data.13, 81, 82 
Figure 3  Hierarchical cluster analysis (HCA) on 1H NMR urine spectra, the INTERMAP 
Study.13 The HCA algorithm produces a dendrogram showing the overall 
similarity/dissimilarity between population samples. Similarity index is normalized to 
intercluster distance. Each branch of the dendrogram defines a subcluster; population 
samples within subclusters are more similar to each other than to those in other subclusters. 
The dendrogram shows clustering based on country, and geographical location or gender.  
Figure 4  The median urinary 1H NMR spectrum of African Americans and non-Hispanic 
white Americans.82  Top: median urinary 1H NMR spectrum of INTERMAP U.S. AA and NHWA 
participants, based on the first urine collection (N=1,455). Bottom: Manhattan plot indicating 
the significant spectral variables. Metabolites higher in AA individuals compared to NHWA are 
shown in red; in blue for metabolites higher in NHWA individuals compared to AA. Key: 1, 
Leucine; 2, 3-hydroxyisovalerate; 3, 2-hydroxyisobutyrate; 4, N-acetyls of glycoprotein 
fragments; 5, N-acetyl neuraminic acid; 6, Succinate; 7, Dimethylamine; 8, Trimethylamine; 9, 
Dimethylglycine; 10, Lysine; 11, Creatinine; 12, Hippurate; 13, N-methyl nicotinic acid. 
 
 
 
 
 
